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ABSTRACT
Brucellosis is a zoonotic infection and has endemic characteristics. Neurobrucellosis is an uncom-
mon complication of this infection. The aim of this study was to present unusual clinical manifesta-
tions and to discuss the management and outcome of a series of 18 neurobrucellosis cases. Initial 
clinical manifestations consist of pseudotumor cerebri in one case, white matter lesions and demy-
elinating syndrome in three cases, intracranial granuloma in one case, transverse myelitis in two 
cases, sagittal sinus thrombosis in one case, spinal arachnoiditis in one case, intracranial vasculitis 
in one case, in addition to meningitis in all cases. Eleven patients were male and seven were female. 
The most prevalent symptoms were headache (83%) and fever (44%). All patients were treated with 
rifampicin, doxycycline plus trimethoprim-sulfamethoxazole or ceftriaxone. Duration of treatment 
(varied 3-12 months) was determined on basis of the CSF response. In four patients presented with 
left mild sequelae including aphasia, hearing loss, hemiparesis. In conclusion, although mortality is 
rare in neurobrucellosis, its sequelae are signifi cant. In neurobrucellosis various clinical and neu-
roradiologic signs and symptoms can be confused with other neurologic diseases. In inhabitants 
or visitors of endemic areas, neurobrucellosis should be kept in mind in cases that have unusual 
neurological manifestations. 
Keywords: neurobrucellosis; serology; diagnosis; neuroimaging.
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INTRODUCTION
Human brucellosis is a common infectious dis-
ease with 18,000 new cases per year in Turkey. 
It still remains a common problem in some 
parts of Turkey because of the consumption 
of contaminated milk or dairy products made 
from unpasteurized milk. Brucellosis seroposi-
tivity is 2.6-14.4% among Turkish people.1
Brucellosis has a wide clinical polymor-
phism and almost every organ can be affected 
during the infection. This infection is primarily 
a reticuloendothelial system (RES) disease, and 
the most common site involved is the osteoar-
ticular. Additionally, hematologic system, cen-
tral nervous system, cardiopulmonary system 
and genitourinary system can be involved to 
some extent.2-5
The incidence of neurological complica-
tions range between 0-25% in adult patients, it 
is rarely seen in children.2,7 Neurological com-
plications are infrequent but have marked clin-
ical importance for their severity and impor-
tant morbidity. Brucella bacteria may affect the 
nervous system directly or indirectly, as a result 
of cytokine or endotoxin on the neural tissue.8 
Cytotoxic T lymphocytes and microglia activa-
tion play an immunopathologic role in this dis-
ease.9 Some immunological mechanisms oper-
ate to produce the demyelinating lesions in the 
cerebral and spinal cord white matter. 
CNS involvement is generally in menin-
goencephalitis form.5,8,9 Development of basal 
meningitis may lead to lymphocytic pleocyto-
sis, cranial nerve involvement or intracranial 
hypertension. In diagnosing brucellosis the 
bacteria isolation from serum and other 
specimens are the gold standard, but cul-
ture positivity may be less than 50% in many 
reports.2-5,8,10,11
In neurobrucellosis imaging fi ndings may 
be found in four types; normal, inﬂ ammation 
(abnormal enhancement), white matter chang-
es, and vascular changes.2,4 Concerning treat-
ment of brucellosis, monotherapy can cause 
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relapses, therefore, combined therapy is recommended. 
The aim of the study was to present different neurologi-
cal conditions ranging from meningoencephalitis, spinal 
arachnoiditis, sagittal sinus thrombosis and transverse my-
elitis to white matter involvement and raised intracranial 
pressure and to discuss managing and response to therapy 
of neurobrucellosis.
MATERIAL AND METHODS 
This prospective study included 18 consecutive patients 
with neurobrucellosis, diagnosed and treated between 2002 
and 2008. Eleven of them were followed up at the infec-
tious diseases clinic and the other seven patients who had 
neurological disorder-like clinic features were followed up 
at the neurology clinic. All patients had diagnostic criteria 
for neurobrucellosis. These were:
1- Signs and symptoms of neurological disease in the 
absence of other diseases.
2- Bacteria isolation from blood and other body ﬂ uids.
3- Standard tube agglutination (STA) titers positivity 
in serum and/or cerebrospinal ﬂ uid (CSF).
4- CSF fi ndings, revealing chronic meningitis (lym-
phocytic pleocytosis, increased protein level, decreased 
glucose level). Presence of any of these four criteria was 
suffi cient for the diagnosis.2,5,8,11
STA commercial kit was obtained from Pendik Vet-
erinarian Research Institute (Istanbul-Turkey). Anti-
body positivity > 1/160 in serum, and > 1/80 in CSF, or 
weekly antibody titer increase was considered diagnostic 
for brucellosis. 
Blood and CSF were cultured in routine aerobic and 
anaerobic automated Bactec system (Bactec 9120 Becton 
Dickinson). Brucella species were identifi ed at the Pendik 
Veterinarian Research Institute.
All cases were evaluated according to their clinical 
symptoms, neurological and physical signs and CSF analy-
sis, as well as backbone x-rays. Chest x-rays were taken to 
rule out possible lung tuberculosis. All CSF samples were 
tested by Gram stain, Ziehl- Nielsen stain and VDRL and 
serum samples by TPHA. Autoimmune disorders were 
ruled out in a patient who had cerebral thrombosis.
In all patients, neuroimaging techniques, such as com-
puted topography (CT) and magnetic ressonance imaging 
(MRI), were performed at the onset of illness and during 
the follow-up period. In our clinic the follow-up protocol 
for neurobrucellosis patients is as follows. After initiation 
of treatment LP is performed in all patients once a month 
to evaluate CSF response to treatment. Cranial CT/MR 
were repeated in patients with intracranial lesions with in-
tervals of 3-4 weeks. Duration of therapy was determined 
according to examination results. During a period of three 
years after discontinuation of treatment the patients were 
checked in our outpatient clinic every 3-6 months. 
RESULTS
The clinical and neuroradiological presentations of pa-
tients with neurobrucellosis are summarized in Table 1.
Eleven patients were male and seven female. The 
mean age was 38.11 ± 18.12. All patients had diagnos-
tic criteria 1, 3, and 4 listed above. Nine patients, who 
had positive blood culture for brucellosis met all diag-
nostic criteria. The cases were classified in two different 
clinical categories. The first group had meningovascular 
complications as prominent signs. Eleven patients (cases 
8-18) had presented symptoms and signs such as fever, 
neck stiffness, cranial nerve palsies. These symptoms 
were considered as a central nervous system infection 
and they were admitted to the infectious disease clinic. 
The second clinical group had implied diffuse CNS in-
volvement. In this group, brain or spinal cord involve-
ment were prominent signs. The patients (cases 1-7) 
had presented with symptoms such as cerebellar dys-
functions, transverse myelitis, neurosensorial deafness, 
hemiplegia, and aphasia. They were admitted to the 
neurology clinic. However there were overlaps among 
the clinical categories. 
Twelve patients were admitted with symptoms other 
than meningitis, although all patients have meningeal 
involvement. The cranial MR of three patients (case 1, 
2, and 8) that had CNS involvement, white matter le-
sions (Figure 1) were observed. For these patients dif-
ferential diagnosis from demyelinating disorders was 
made. In three patients (case 5, 7, and 17), myelitis was a 
Figure 1: White matter lesions on T2 weighted MRI scanning 
(case 1).
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Table 1. Summary of the clinical features and cranial CT/MR of patients with neurobrucellosis
 p A S Neurological Diagnosis Cranial CT/MRI Serum CSF
     symptoms and signs  SAT titers SAT titers
 1 45 F Papilledema,  Meningoencephalitis White matter 1/640 1/320
    intentional tremor  lesions (MR)
 2 51 M Hearing loss (bilateral Meningoencephalitis Meningeal contrast (MR)  1/320 1/160
    neurosensorial auditory   enhancement white     
    loss), dysmetria, ataxia  matter lesions
 3 36 M Diplopia, right abducens Meningoencephalitis Meningeal contrast (MR)  1/320 1/160
    palsy, motor aphasia,   enhancement
    right hemiparesis 
 4 45 F Depression, Meningitis plus Meningeal contrast (MR)  1/640 1/160
    papilledema Intracranial hypertension enhancement
 5 63 F Quadriparesis (3/5),  Meningomyelitis Spinal MR: cervical 1/320 1/180
    bilateral dysesthesia below T2,   medulla spinalis involvement
    urinary and anal incontinans
 6 55 M Motor aphasia, Vasculitis Infarction of left MCA (CT) 1/2560 ND
    right hemiparesis (left MCA infarct)
 7 35 F Imbalance, lower Meningomyelitis Pachymeningeal 1/640 1/320
    extremity contraction,   contrast enhancement
    micturition disturbances  in spinal cord (spinal MR)
 8 51 F Confusion, quadriparesis Meningoencephalitis White matter lesions (MR) 1/320 1/160
 9 36 M Confusion Meningoencephalitis CT and MR normal 1/640 1/160
 10 15 M Confusion Meningoencephalitis Meningealcontrast enhancement 1/320 1/80
 11 22 F Diplopia, lower Meningoencephalitis  Spinal MR 1/320 1/80
     extremity paraparesis + spinal arachnoiditis
      inflammation of MS
 12 17 M Diplopia, Meningoencephalitis  Granuloma in left 1/160 1/80
    imbalance,speech + intracranial temporal lobe, vasculitis 
    disturbances, left nervous  granuloma
    abducens palsy
 13 14 M - Meningitis CT and MR normal 1/640 1/80
 14 26 F - Meningitis CT and MR normal 1/640 1/160
 15 29 M Aphasia, sensory  Meningoencephalitis Cranial MR venography:  1/320 1/80
    loss in the upper and   sagittal sinus thrombosis
    lower extremities, confusion
 16 14 M - Meningitis CT and MR normal 1/640 1/160
 17 67 M Quadriparesis (3/5),  Meningomyelitis CT and MR normal SAT(-), IgM  SAT(-), IgM 
    micturition disturbances,   and  and 
    nistagmus   IgG(+)* IgG(+)*
 18 65 M - Meningitis CT and MR normal 1/1280 1/160
P, patients; A, age; S, sex; MS, Medulla spinalis; ND, not done. 
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prominent sign at clinical and radiological examination 
(Figure 2). In case 4, who had pseudotumor cerebri pre-
sented CSF pressure of 600 cmH2O at the lumbar punc-
ture. Case 6 had history of aortic valve replacement due 
to rheumatic heart disease. In his neurological examina-
tion, he had right hemiparesis and motor aphasia. The 
patient was admitted to the infectious disease clinic due 
to preliminary diagnosis of Brucella endocarditis and 
neurobrucellosis. Transesophageal echocardiography 
detected a mass sized 4 x 3.5 x 2 cm in the base of the 
aorta, which was presumed to be an abscess. He under-
went an operation for abscess removal and replacement 
of aorta valve. In case 10 a swelling was observed in his 
Figure 2: A. The patchy contrast enhancement on T1 weighted MRI scanning. B. Fusiform transverse myelitis 
at level C 3,4,5 on T2 weighted MRI scanning (case 5).
left parotid on the third day of Brucella treatment. Anti-
mumps IgM was negative. White blood cell count, poly-
morphonuclear leucocytes and CRP were not suggestive 
of acute suppurative parotitis. Repeated serum mumps 
IgM was negative at the 14th day. His parotitis improved 
at the 13th day of brucellosis therapy. His cranial MR 
showed a meningeal enhancement on T1 (Figure 3). In 
case 11, knee pain and walking disturbance emerged in 
the 25th day. In her neurological examination parapare-
sis and tremor were detected. The spinal MRI revealed 
inflammation throughout the spinal canal and arach-
noiditis. Case 12 had complaints of weakness, speech 
disturbance, double vision and imbalance for two weeks. 
Figure 3: Wide meningeal enhancement on T1 weighted MRI scanning (case 10).
BA
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Figure 4: At right temporal lobe, a granuloma with peripheral enhancement on T1 weighted MRI scanning (case 12).
Figure 5: At level of basal ganglia, vasculitic changes on T1 weighted MRI scanning (case 12).
In his hospital following period, a generalized tonic-clon-
ic seizure was observed. Cranial CT showed a hypodense 
nodule of about 1 cm diameter in the right temporal lobe 
(Figure 4) and MRI results showed vasculitic changes on T1 
at the level of the right basal ganglia (Figure 5). Case 15 pre-
sented with aphasia and sensory loss in the upper and lower 
extremities. Sagital sinus thrombosis was detected in his cra-
nial MR venography.
Fifteen patients had headache since onset of illness. 
Due to some patients having altered consciousness we 
preferred the term of meningoencephalitis. Except one 
(case 13), all patients had a history of using unpasteur-
ized dairy products. In two patients the symptomatic pe-
riod lasted about five and eight months. In the remaining 
patients duration of symptoms ranged from seven days 
to four months (56.88 ± 61.92 days). Eight patients had 
Neurobrucellosis 
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Table 2. Summary of various clinical features of 
neurobrucellosis
Features of patients N (%)
Fever 8 (44.4)
Headache 15 (83.3)
Neck stiffness 5 (27.7)
Positive MR findings 12 (66.6)
Conscious alteration 9 (50)
Myelitis 3 (16.6)
Vascular involvement 3 (16.6)
Cranial nerve involvement 4 (22.2)
Paresia 6 (33.3)
Sequel 4 (22.2)
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fever and five patients had signs of meningeal irritation. 
Cases 9, 10, 14, and 16 exhibited acute onset of menin-
geal syndrome. Two patients had epileptic seizures (case 
2, 12). Other additional neurological manifestations in-
cluded tetraparesis, hemiparesis, cranial nerve involve-
ments and cerebellar findings.
In two cases (1 and 4), patients had depressive mood 
and had received antidepressant for two and eight 
months, respectively, before admission to the hospital. 
CSF analysis findings confirmed lymphocytic pleocy-
tosis (12-750 cells/mm3; mean 250.47 ± 246), increased 
CSF protein level (82-450 mg/dL; mean 171.35 ± 97.51) 
and decreased CSF/plasma glucose ratio (18-45 %; mean 
37.75 ± 14.0). All patients had the diagnosis established 
by STA test. However in three patients (cases 10, 12, and 
17) STA titer had become positive on the 24th, 34th and 
20th days after onset of the disease, respectively.
In nine patients serum cultures were positive for 
Brucella species. Three of the nine isolates were identi-
fied as B. melitensis. CSF immune electrophoresis was 
performed in patients who had white matter lesions ra-
diologically. Oligoclonal band was negative in CSF and 
serum immune electrophoresis of these patients .
For each patient, the highest titer was given for stand-
ard agglutination test results in Table 1. 
Chest x-rays and backbone x-rays were within nor-
mal limits in all patients. Neuroimaging findings were 
normal in six patients. The pathologies observed in neu-
roradiological examinations consisted of meningeal con-
trast enhancement, white matter changes, and vascular 
changes that were correlated with the clinical manifesta-
tions. 
Antimicrobial therapy consisted of a combination of 
three drugs; doxycycline and rifampicin were used in all 
patients, and the third drug was one of either co-trimox-
azole, ceftriaxone, or ciprofloxacin. In four patients cef-
triaxone was used at onset of therapy and was changed to 
co-trimoxazole after three or four weeks. Ciprofloxacin 
was used in only two patients who had gastric intoler-
ance and allergic reaction to co-trimoxazole. Duration 
of treatment was determined according to CSF response 
ranging from three months to one year. The patient who 
had pseudotumor cerebri (case 4) used acetazolamide to 
reduce intracranial pressure. Two patients had initially 
received tuberculostatics without improvement (case 10 
and 12). In the 5th and 7th cases neurobrucellosis exacer-
bated six months due to the cessation of treatment them-
selves.
For the four patients (cases 5, 7, 11, 12) who had cra-
nial nerve involvement and toxicity, prednisolone was 
used.
Fourteen patients recovered without any sequelae. In 
four patients some neurological deficits persisted. Two 
patients had neurosensorial deafness (cases 2, 7), one had 
tetraparesis (case 5), and one had hemiparesis and motor 
aphasia (case 6). Remarkable features of our patients are 
summarized in Table 2.
DISCUSSION
Brucellosis is a common endemic infection in Turkey. 
Although mortality of brucellosis is rare, it continues to be a 
major health problem because of its morbidity. 
In this infection male-to-female ratio is 2:1 in the litera-
ture.11 This may reﬂ ect occupational risks such as stock in-
dustry, which mostly employs males. In our series the male-
to-female ratio was 1.57:1. Our patients may have acquired 
the disease from unpasteurized dairy product, thus it was 
not gender associated as reported in the literature.
Infection triggers the immune mechanism leading to a 
demyelinating state.9 In our fi rst case meningoencephalitis 
leading to perivascular white matter lesions suggests this 
immunopathology. Brucellosis caused transverse myelitis in 
cases 5 and 7. Similar immunopathogenesis may be respon-
sible in these cases, too. As the disease gets more chronic, the 
immune mechanism processes increase.9 Encephalopathy 
in brucellosis is always secondary to vascular involvement. 
Cranial nerve paralyses were seen more frequently during 
the acute/subacute disease course associated with diffuse 
CNS involvement. The acoustic nerve was described as the 
most frequently involved cranial nerve.6,7,11 Two of our pa-
tients had developed neurosensorial deafness associated 
with eighth nerve involvement. In three patients, n. abducens 
and n. facialis paralyses were found respectively.
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The treatment of neurobrucellosis is still controver-
sial.2-6 There are few guidelines for the appropriate duration 
neurobrucellosis treatment.25 Recent reports recommend a 
regimen with a combination of three or four antibiotics 
for neurobrucellosis.11 Doxycycline is the preferred tetra-
cycline in neurobrucellosis because its tissue and CNS pen-
etrance is much better and it also has a longer half-life. Ri-
fampicin and co-trimoxazole also offer a good penetration 
into the CSF.25 Ciproﬂ oxacin combined (not solely26) with 
other antibiotics is as effective as the standard regimen of 
doxycycline and rifampicin.27,28 Ceftriaxone also offers good 
in vitro activity and penetration into the CSF.29 Ceftriaxone 
alone was given to three patients at onset of disease until 
defi nite diagnosis. With this antibiotic signs and symptoms 
abated. Ceftriaxone can be chosen as the third antibiotic in 
the hospitalization period or for a patient for whom oral 
antibiotic could not be given. In neurobrucellosis treatment 
should be maintained until improvement of clinical symp-
toms and CSF response. Serological fi ndings have little value 
to decide when to stop therapy.
In our patients treatment was generally fairly well tol-
erated. Co-trimoxazole caused gastric intolerance and al-
lergic reaction in only two patient, for whom ciproﬂ oxacin 
was used instead. In a previous study, gastric intolerance 
was reported in two of 86 patients.30
Prognosis of neurobrucellosis varies according to 
clinical presentation; for example, in the meningitis 
group the prognosis was usually good. However, in the 
encephalic or spinal cord involvement, mortality is not 
negligible and sequelae are more frequent. In this series 
neurological sequelae were observed in the group with 
diffuse CNS involvement. It is clear that adequate dura-
tion of therapy and appropriate combination of antibiot-
ics may prevent recurrence.
In summary, (I) brucellosis may initiate demyelinating 
process like as seen in the 1st, 2nd, and 8th cases; (II) brucellar 
meningitis may be the only sign of brucellosis, as in 9th case or 
it may be fi rst sign of brucellosis as in 10th case; (III) the com-
plication may be silent, part of systemic brucellosis as in 13th, 
16th, and 18th cases, and it may be overlooked; (IV) it also may 
be confused with tuberculous meningitis as the 11th and 12th 
cases; (V) during the fi rst weeks of the disease, specifi c immune 
response may be delayed in serum and/or CSF like as observed 
in the 10th, 12th, and 17th cases; therefore, serologic tests should 
be repeated weekly, particularly in endemic regions.
CONCLUSION
Brucellosis continues to be a common and important health 
problem in developing countries and neurobrucellosis is one of 
the important complications of brucellosis. Neurobrucellosis 
may appear with different clinical manifestations and the diag-
nosis may be diffi cult. In unusual neurologic disorders brucel-
losis should be kept in mind especially in endemic areas.
Neurobrucellosis
Our fourth case had an intracranial hypertension which 
developed as migraine-like headache and symptoms. Head-
ache and psychiatric symptoms may develop due to the toxic 
effect of neurobrucellosis, but intracranial hypertension is 
a result of meningoencephalitis. Spinal arachnoiditis devel-
oped in our 11th patient as a result of inﬂ ammation.
As noted in previous reports, the sign and symptoms of 
meningeal involvement are non-specifi c in neurobrucello-
sis.3 Neck stiffness occurs in less than one half of patients 
with meningitis. In our series, neck stiffness or Kernig’s and 
Brudginsky’s signs were observed only in fi ve patients. The 
reason for the infrequent meningeal signs may be the chro-
nicity of the infection.
Although endocarditis, hepatitis, epididymo-orchitis, 
spondylitis or abscess are reported in brucellosis patients, no 
report is found about the parotitis originating from brucel-
losis.3-18 Parotitis seen in our 10th patient was not related to 
mumps. There was no fi nding suggestive of bacterial etiolo-
gy. However, the parotid gland swelling emerged during the 
meningitis and improved with continued brucellosis ther-
apy. We thought that parotitis was caused by brucellosis.
In our series, serum culture positivity was 50% for 
B. melitensis was the most commonly isolated species from 
neurobrucellosis cases. This may be for its being more neu-
rotropic than other Brucella spp. CNS involvement is rare 
with other Brucella species.2,3,11 B. melitensis was isolated 
from the serum of only two of our patients. Brucella was 
never isolated from the CSF. We thought this was due to low 
bacteria density and that CSF was inoculated in nonspecifi c 
agar medium at the onset of the disease. Although ELISA is 
a sensitive and specifi c test for the diagnosis of neurobrucel-
losis, the most commonly used method for screening is the 
standard agglutination test.19-21 Antibody titers in CSF are 
usually lower than in serum. In some patients agglutination 
test is negative at the beginning of the illness, this is a well 
known feature in localized brucellosis and sometimes more 
than one serologic test is necessary before it turns out posi-
tive.4-6 In the 9th and 10th cases, despite positive serum STA 
during the hospitalization, CSF STA turned out positive at 
15th and 24th day of treatment, respectively. In the 12th case, 
serum and CSF STA titers and Brucella IgG and IgM titers by 
ELISA were negative until the 34th day. 
In neurobrucellosis there are four imaging fi ndings; nor-
mal, inﬂ ammation (abnormal enhancement), white matter 
changes, and vascular changes.22 In this series the four im-
aging presentations were observed. Although granuloma-
tous formation results from inﬂ ammation that is relevant 
to infection, it is a rare manifestation in neurobrucellosis.23 
This disease does not show predilection of size or location of 
vascular structure. Arterial and/or venous structures may be 
affected.24 Although in diagnosis of disease imaging results 
are not specifi c, it also contributes in the monitoring of nor-
malization of the pathology during follow-up .
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